Stocks To Buy Forum

Stocks to Buy based on the Best Stock Market Research

John James
  • Male
  • Frankfurt
  • Germany
Share

John James's Discussions

AXSM (MC $83 M)(Cash $50 M) 4x BIG Phase 3 in various indication ongoing =TOP PICK
1 Reply

Very attractive and massive undervalued Biotech Stock with many Major News on the way . Axsome has 4 Phase 3 clinical trials ongoing in various indication targeting very large Markets .This Stock is…Continue

Started this discussion. Last reply by John James on Monday.

RDHL (MC $150 M) $60+ M Cash / 3 MEGA Drugs with P3 results in 1H 2017
1 Reply

RDHL is a brutally undervalued and almost unknown gem with many News coming within 6-7 months including Phase 3 Results from 2 Potential Blockbusters and NDA resubmission in early 2017 . Market Cap…Continue

Started this discussion. Last reply by John James Dec 27, 2016.

AQSZF (MC $10 M) 2 Marketed Drugs & 3 Drugs nearing Approval = FANTASTIC OPP
3 Replies

This completely undiscovered low float is definitely one of the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry…Continue

Started this discussion. Last reply by John James Mar 2.

IGXT (MC $32 M) 2 FDA approvals coming + 2 New NDA Submissions in 4Q = 10+ BAGGER EASILY
5 Replies

Undiscovered Intelgenx (IGXT) is definitely one of the most attractive and undervalued stock in the Biotech Sector . The Company has already 2 Drugs approved and another 2 Big Drugs close to FDA…Continue

Started this discussion. Last reply by John James Aug 22, 2016.

 

John James's Page

Latest Activity

John James replied to John James's discussion AXSM (MC $83 M)(Cash $50 M) 4x BIG Phase 3 in various indication ongoing =TOP PICK
"maybe the cheapest Nasdaq Biotech you can get with 5x Phase 3 in various indications and a laughable Market cap of $85 Million and $50 Million in cash .The fair value should be at $8-10 right now for this unknown Biotech .Latest stock market analyst…"
Monday
John James posted a discussion

AXSM (MC $83 M)(Cash $50 M) 4x BIG Phase 3 in various indication ongoing =TOP PICK

Very attractive and massive undervalued Biotech Stock with many Major News on the way . Axsome has 4 Phase 3 clinical trials ongoing in various indication targeting very large Markets .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .This undiscovered goldmine could be the next 10 bagger gem if just…See More
Mar 22
John James replied to John James's discussion AQSZF (MC $10 M) 2 Marketed Drugs & 3 Drugs nearing Approval = FANTASTIC OPP
Mar 2
John James replied to John James's discussion AQSZF (MC $10 M) 2 Marketed Drugs & 3 Drugs nearing Approval = FANTASTIC OPP
"Great Video shows again the mega potential here https://www.youtube.com/watch?v=jV00WmYBtv4"
Feb 24
John James replied to John James's discussion AQSZF (MC $10 M) 2 Marketed Drugs & 3 Drugs nearing Approval = FANTASTIC OPP
"Got a great Reply by Ceo Janzen ..this unknown Goldmine should be at $2+ right now ...Bought my shares back in last few days . djanzen@aequuspharma.ca Jan 6 at 10:13 PM Hello XXX and Happy New Year… Thanks for your email. The share…"
Jan 11
John James posted a discussion

AQSZF (MC $10 M) 2 Marketed Drugs & 3 Drugs nearing Approval = FANTASTIC OPP

This completely undiscovered low float is definitely one of the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry .Aequus has begun to Market 2 Drugs called Vistitan (Glaucoma) and Tacrolimus IR (Transplant) in first half 2016 in Canada and they got the Canadian rights for the Epilepsy drugs Trokendi XR and Oxtellar XR from Supernus Pharma (SUPN) earlier this year , NDS submission for Approval is expected in…See More
Sep 21, 2016
John James replied to John James's discussion IGXT (MC $32 M) 2 FDA approvals coming + 2 New NDA Submissions in 4Q = 10+ BAGGER EASILY
"Shorts tried hard to kill momentum yesterday but they will lose the Game because the Stock is terrible Undervalued und there is to much News on the way so every dip below $1 is a great buying opportunity . IntelGenx Technologies Corp…"
Aug 9, 2016
John James replied to John James's discussion IGXT (MC $32 M) 2 FDA approvals coming + 2 New NDA Submissions in 4Q = 10+ BAGGER EASILY
"IGXT start moving get some before she explodes higher ,Big News like Partnership(s),NDA submissions and new approvals in EU on the way . Market cap of $35 Million is more than ridiculous .Fair Value is minimum…"
Aug 1, 2016
John James replied to John James's discussion IGXT (MC $32 M) 2 FDA approvals coming + 2 New NDA Submissions in 4Q = 10+ BAGGER EASILY
"Here is one of the reason why i like this stock so much is because of this  thin-flim version of the Blockbuster Cialis which works faster than tablet . There are NO generics available on the Markets so IGXT could capture a significant market…"
Jul 27, 2016
John James replied to John James's discussion IGXT (MC $32 M) 2 FDA approvals coming + 2 New NDA Submissions in 4Q = 10+ BAGGER EASILY
"Strong Insider & Institutional Ownership on this Goldmine . Big Jump to new highs could come anytime now .GLInsider Ownership : Horst G. Zerbe 4,670,243.5 7.34% Ingrid Zerbe 5,471,356.5 8.60% Bernard J. Boudreau 287,500 Bernd Melcher 232,500…"
Jul 26, 2016
John James posted a discussion

IGXT (MC $32 M) 2 FDA approvals coming + 2 New NDA Submissions in 4Q = 10+ BAGGER EASILY

Undiscovered Intelgenx (IGXT) is definitely one of the most attractive and undervalued stock in the Biotech Sector . The Company has already 2 Drugs approved and another 2 Big Drugs close to FDA approval .BIG Partnership News could come any day for up to 3 Drugs for which IGXT got a Therm Sheet from a Global Pharma Company and there is another partnering discussion ongoing for 2 Drugs (see pipeline chart below) .IGXT has a ridiculous Market Cap of less than $32 Million which is a Big Joke for a…See More
Jul 21, 2016
John James replied to John James's discussion IPCI (MC $44 M) 8 Drugs awaiting FDA approval =1000%+ Potential !!!
"once the stock retake the MA(50) at 1.80 then quick jump back over $2 coming . IPCI is still one of the most undervalued Biotechs out there [img]http://finviz.com/chart.ashx?t=IPCI&ty=c&ta=1&p=d&s=l[/img]"
Jun 23, 2016
John James posted a discussion

IPCI (MC $44 M) 8 Drugs awaiting FDA approval =1000%+ Potential !!!

IPCI has a very large and attractive Product Pipeline with 8 Drugs awaiting FDA approval which could they could approved anytime now . Their Key Drug is Rexista a potential Best in Class Abuse Deterrent  Pain Drug with HUGE Market Potential . NDA Filing for the Drug is planned within Weeks (June or July) .We could see $5++ easily with NDA filing and Runup to FDA decision (4Q16 or early 1Q2017) and much higher if there is any approval of the Drugs under review by FDA . This ultra Low float Stock…See More
Jun 2, 2016
John James replied to John James's discussion AYTU (MC $13 M) (Cash $15 M) MEGA Drug launch in July ($2+ BILLION Market)
"Aytu is definitely oneof the cheapest Biotechs out there but this will change quickly once investors discover this Goldmine .GLAYTU – Expanding Men’s Urology Portfolio...... By Zacks Small Cap ResearchMay 25, 2016 4:30…"
May 27, 2016
John James posted a discussion

AYTU (MC $13 M) (Cash $15 M) MEGA Drug launch in July ($2+ BILLION Market)

Here is an undiscovered Stock with Monster Upside Potential  which just trading at cash level . Aytu Biosciences bought US Rights to Natesto the only [b]approved[/b] testosterone nasal gel which targets a $2+ BILLION Market which they start selling in July . The Company has another 3 Products on the Market and another One Big drug ready for Phase 3 . AYTU has a ridiculous Market Cap of just $13 Million which is below the Cash balance of $15 Million means you get the Company and Products for…See More
May 26, 2016
John James replied to John James's discussion INNV (MC $4 M) 13 Products on Market +BIG FDA approval in 1H 2016
"Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN) http://finance.yahoo.com/news/upcoming-pdufa-anda-approval-dates-140000806.html Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13…"
May 16, 2016

Comment Wall

You need to be a member of Stocks To Buy Forum to add comments!

Join Stocks To Buy Forum

  • No comments yet!
 
 
 

Stocks to Buy 2017

Stocks to Buy 2017

Small Cap Bull 3x (TNA)
Shake Shack (SHAK)
Stocks to Watch - 2017
Penny Stocks - 2017



Twitter - Free Stock Alerts

© 2017   Created by Stocks To Buy.   Powered by

Badges  |  Report an Issue  |  Terms of Service